Eledon Pharmaceuticals/$ELDN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eledon Pharmaceuticals
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Ticker
$ELDN
Sector
Primary listing
Employees
31
Headquarters
Website
ELDN Metrics
BasicAdvanced
$122M
-
-$1.10
0.75
-
Price and volume
Market cap
$122M
Beta
0.75
52-week high
$4.60
52-week low
$1.35
Average daily volume
3M
Financial strength
Current ratio
6.736
Quick ratio
6.586
Long term debt to equity
0.413
Total debt to equity
0.793
Profitability
Effective tax rate (TTM)
-0.54%
Management effectiveness
Return on assets (TTM)
-44.22%
Return on equity (TTM)
-95.49%
Valuation
Price to book
1.07
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-1.826
Free cash flow yield (TTM)
-54.77%
Free cash flow per share (TTM)
-0.893
Growth
Earnings per share change (TTM)
-49.04%
3-year earnings per share growth (CAGR)
-25.57%
ELDN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eledon Pharmaceuticals stock?
Eledon Pharmaceuticals (ELDN) has a market cap of $122M as of December 17, 2025.
What is the P/E ratio for Eledon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eledon Pharmaceuticals (ELDN) stock is 0 as of December 17, 2025.
Does Eledon Pharmaceuticals stock pay dividends?
No, Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders as of December 17, 2025.
When is the next Eledon Pharmaceuticals dividend payment date?
Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.